The effect of a steroid "burst" and long-term, inhaled fluticasone propionate on adrenal reserve

Annals of Allergy, Asthma and Immunology

Volumn 91, Issue 1, 2003, Pages 38-43

  Nguyen, Kim Lien ^a   Lauver, David ^a   Kim, Isaac ^a   Aresery, Matthew ^a,b  

^a READING HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE; HYDROCORTISONE; PREDNISONE; TETRACOSACTIDE;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ADULT; ALLERGIC RHINITIS; ARTHRALGIA; ARTICLE; ASTHMA; BRONCHITIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIARRHEA; DRUG MEGADOSE; EDEMA; FATIGUE; FEMALE; FEVER; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NIGHT SWEAT; NOSE POLYP; PERSONALITY DISORDER; PRIORITY JOURNAL; SKIN BRUISING; THIRST; URTICARIA;

EID: 0042344921     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62056-X     Document Type: Article

References (27)

1. NAEPP Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma: Update on Selected Topics 2002. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; June 2002. Publication 97-4051.
2. Robinson DS, Geddes DM. Inhaled corticosteroids: benefits and risks. J Asthma. 1996;33:5-16.
3. Geoffrey T, Wright D, Ryan M. Acute adrenal insufficiency in a patient with asthma after changing from fluticasone propionate to budesonide. J Allergy Clin Immunol. 1999;103:956-957.
4. Gogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids. 1994;59:597-602.
5. Esmailpour N, Hogger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J. 1997;10:1496-1499.
6. Leonard MT, Lewis SB. The low dose (1-μg) adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency. J Clin Endocrinol Metab. 1998;83:2726-2729.
7. Tordjman K, Jaffe A, Grazas N, Apter C, Stern N. The role of the low dose (1 mcg) adrenocorticotropin test in the evaluation of patients with pituitary diseases. J Clin Endocrinol Metab. 1995;80:1301-1305.
8. Streeten DH, Anderson GH Jr, Dalakos TG, et al. Normal and abnormal function of the hypothalamic-pituitary-adrenocortical system in man. Endocr Rev. 1984;5:371-394.
9. Cunningham SK, Moore A, McKenna TJ. Normal cortisol response to corticotropin in patients with secondary adrenal failure. Arch Intern Med. 1983;143:2276-2279.
10. Streeten DH, Anderson GH Jr, Bonaventura MM. The potential for serious consequences from misinterpreting normal responses to the rapid adrenocorticotropin test. J Clin Endocrinol Metab. 1996;81:285-290.
11. Holt PR, Lowndes DW, Smithies E, Dixon GT. The effect of an inhaled steroid on the hypothalamic-pituitary-adrenal axis: which tests should be used? Clin Exp Allergy. 1990;20:145-149.
12. Zarkovic M, Ciric J, Stojanovic M, et al. Optimizing the diagnostic criteria for standard (250-mcg) and low dose (1-mcg) adrenocorticotropin tests in the assessment of adrenal function. J Clin Endocrinol Metab. 1999;84:3170-3173.
13. Park YJ, Park KS, Kim JH, Shin CS, Kim SY, Lee HK. Reproducibility of the cortisol response to stimulation with the low dose (1 mcg) of ACTH. Clin Endocrinol. 1999;51:153-158.
14. Dickstein G, Shechner C, Nicholson WE, et al. Adrenocorticotropin stimulation test: effects of basal cortisol level, time of day, and suggested new sensitive low dose test. J Clin Endocrinol Metab. 1991;72:4:773-778.
15. Streeten DH. Shortcomings in the low dose (1 mcg) ACTH test for the diagnosis of ACTH deficiency states. J Clin Endocrinol Metab. 1999;84:835-837.
16. Streck WF, Lockwood DH. Pituitary adrenal recovery following short term suppression with corticosteroids. Am J Med. 1979;66:910-914.
17. Carella MJ, Srivastava LS, Gossain VV, Rovner DR. Hypothalamic-pituitary-adrenal function one week after a short burst of steroid therapy. J Clin Endocrinol Metab. 1993;76:1188-1191.
18. Levic Z, Micic D, Nikolic J, et al. Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients: clinical assessment by the insulin tolerance test. J Endocrinol Invest. 1996;19:30-34.
19. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000;355:542-545.
20. Marik P, Varon J. Current recommendations for "steroid burst" therapy. Postgrad Med. 2000;107:227.
21. O'Driscoll BR, Kalra S, Wilson M, Pickering CA, Carroll KB, Woodcock AA. Double-blind trial of steroid tapering in acute asthma. Lancet. 1993;341:324-327.
22. Li JT, Goldstein MF, Gross GN, et al. Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol. 1999;103:622-629.
23. Li JT, Ford LB, Chervinsky P, et al. Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol. 1999;103:1062-1068.
24. Chernow B, Alexander HR, Smallridge RC, et al. Hormonal responses to graded surgical stress. Arch Intern Med. 1987;147:1273-1278.
25. Chervinsky P, van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. J Allergy Clin Immunol. 1994;94:676-683.
26. Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax. 1996;51:262-266.
27. Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax. 1997;52:55-58.